SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--AvidBiotics Corp. today announced the receipt of grant from the National Institute of Allergic and Infectious Diseases of the National Institutes of Health to further development of the company’s targetable bactericidal proteins to specifically kill Clostridium difficile bacteria. The new Small Business Innovation Research (SBIR) grant, Award Number R43AI098186, provides AvidBiotics with a total of $600,000 of research funding over two years.